Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gee so no facts whatsoever to refute the facts I've thrown up. Got it. Thanks - LOL LOL!!!
Yes I know I'm correct no need to keep mentioning it......the facts speak for themselves.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=88285341&txt2find=10|bagger
Yes it is - I called the 10 bagger as all here can see. Next
Thanks; Yes no question about it I nailed the 10 bagger and then some!!!
It is simple.......more BS with nothing to back it up as I said there wouldn't be.
Got it just more BS with nothing to back it up. No it doesn't happen all the time or there would be links to back it up........and there won't be. You can't back up what doesn't exist.
Elite nor anybody else paid for that article.
Thanks for the BS but the question still hasn't been answered.
Still doesn't answer my question. The existing ADFs that have PBM backing.......how did they get it?
Got it so no proof even in the slightest that it was a paid promotion particularly when it is stated publicly that it isn't a paid promotion.
I'm sorry the 9 ADTs that the FDA has already approved.......how did those companies obtain PBM backing?
Got it so we throw the following in the trash where these belong: BK, RS, .02 cent "SOON", sub penny, SequestOx is put on the shelf for good and Elite will never have enough money for a phase 3 trial.
LMAO - you do realize the FDA isn't going to stop approving opioids right........and will begin to push for ADT opioids instead.
LMAO; the FDA created this problem in the first place and they'll be lucky to slow it down. The FDA is so tied to big pharma and it isn't going to stop approving pain killers that is for certain. They had best move all opioids to abuse deterrent opioids.
LMAO!!!! Total BS - that's not a warning letter at all. Not to mention Elite doesn't manufacture either one of those drugs - Vivitrol or Suboxone.
I've heard the same BS since .06 cents and then it ran to .97 cents.
The next run moves Elite passed a $1.
MORE GOOD NEWS: • Abuse-deterrent formulas. FDA is preparing for an expected onslaught of generic versions of these drugs — which currently don't exist — and will release guidance for drugmakers soon. Abuse-deterrent drugs can actually lead to riskier behavior, as FDA learned with the drug Opana ER. FDA asked the maker of the purportedly safer opioid to withdraw it in June because a reformulated version led users to inject it. That led one Indiana county to have the highest number of HIV cases in the U.S.
Elite has filed the first generic ADT opioid.
https://www.usatoday.com/story/news/politics/2017/10/23/fda-chief-supports-opioid-prescription-limits-regrets-agencys-prior-inaction/774007001/
10 FACTS of LIGHT leading to DOLLARLAND = $$$$$$$$$
1) It's important to keep in mind, and as Nasrat will discuss, our resources are being increasingly focused on our generic and opioid pipeline, and preparing for the launch of the generic products already filed with the FDA, as well as the generics which are licensed currently to Epic that will be coming back to Elite in late 2018, when that license expires.
our business is moving away from this type of revenue stream that is dependent on third parties.
2) the resources which were previously utilized for contract manufacturing were allocated to product development. Instead of making Methadone batches, these resources were used to run batches in products which are under development. In addition, we extended our lab and regulatory personnel to support this greatly increased product development activities.
The level of product development activity is the highest that I've seen since I've been here. And I've been with Elite since 2009.
3) there are three ANDAs already filed and under active review with the FDA. Also several other products in various stages of development that we expect will result in more ANDA filings over the near and mid-terms.
4) SequestOx - We are right now focusing on evaluating the right path forward for us to resolve this issue. Epic is negotiating and engaged with us. We've received several phone calls from them, offering their help and we made the announcement regarding the fat study.
5) Our ER products and pipeline are moving forward - And we are pursuing ER formulations. As a matter of fact, most of the money is in the ER extended release formulation
6) We started our aggressive program of filing one ANDA per quarter in Q3 of 2016. We filed one then and we filed another one in Q4, and a third in Q1 of 2017. We missed Q2 of 2017. We are scheduled to file one in Q3 of this year, so it's going to happen way before the end of this quarter and we are scheduled to file another one in Q4 by December.
7) The FDA has granted us 12-month extension for resubmission. One of my main concerns was if we missed this date by December of this year, which we will - that we will end our PDUFA fee and then we'll have to pay another one. We communicated with the FDA and they give us a 12-month extension. Now we can file any time in 2018 up to and through December 31, 2018 without asking for another extension if needed. And if the results are valid, we can proceed within that timeframe without paying another PDUFA fee.
8) we have many other valuable products that are progressing rapidly right now. At Elite, when we were manufacturing a little more, the number of [entries that I remember on our study] [ph] was about 13. And now, we're up to 50 and growing. And the reason we're growing even though the manufacturing part is not our primary focus and small, is because of all of these projects that are going to lead us within the next couple of years to becoming a seriously viable company. FYI, the total market size of the pipeline products that we are co-developing with SunGen is $6 billion.
9) All Elite needs is about $50 million in profit for our stock to go to dollar land, do the math. For our future growth, Elite pipeline will be the driver. We want to ensure a high rate of revenue growth by aggressively targeting one ANDA filing each quarter. Okay. As I stated earlier, out of the last four quarters we have submitted three ANDAs. We are scheduled to submit one this quarter and one in the quarter after.
10) we have completed the expansion of our manufacturing facility in preparation for our new product approval and launches.
Gee so no proof that this article was a paid promo. Why? Because there was no paid promotion period. Like I said there will be no proof provided. WHOOPSY!!
But I have have proof yet again. This is what it states at the end of the article.
https://insiderfinancial.com/here-are-two-ways-elite-pharmaceuticals-inc-otcmktseltp-could-win-from-generic-oxycontin
Disclosure: We have no position in ELTP and have not been compensated for this article.
Total BS - it wasn't a paid promotional article.......or else proof of it would be able to be provided. It won't be because you can't prove what doesn't exist. Next
$SXCP - SXC just continues to buy more and more shares.
Sun Coal & Coke Llc Purchases 18,284 Shares of SunCoke Energy Partners, L.P. (SXCP) Stock https://www.americanbankingnews.com/2017/10/25/sun-coal-coke-llc-purchases-18284-shares-of-suncoke-energy-partners-l-p-sxcp-stock.html
On Monday, October 23rd, Sun Coal & Coke Llc purchased 9,817 shares of SunCoke Energy Partners, L.P. stock. The stock was bought at an average cost of $17.71 per share, with a total value of $173,859.07.
On Friday, October 20th, Sun Coal & Coke Llc acquired 7,900 shares of SunCoke Energy Partners, L.P. stock. The stock was acquired at an average price of $17.81 per share, for a total transaction of $140,699.00.
On Wednesday, October 18th, Sun Coal & Coke Llc acquired 7,900 shares of SunCoke Energy Partners, L.P. stock. The stock was acquired at an average price of $17.78 per share, for a total transaction of $140,462.00.
On Tuesday, October 17th, Sun Coal & Coke Llc acquired 8,800 shares of SunCoke Energy Partners, L.P. stock. The stock was acquired at an average price of $17.77 per share, for a total transaction of $156,376.00.
On Tuesday, October 10th, Sun Coal & Coke Llc acquired 7,830 shares of SunCoke Energy Partners, L.P.
stock. The stock was acquired at an average price of $17.48 per share, for a total transaction of $136,868.40.
On Wednesday, October 11th, Sun Coal & Coke Llc acquired 16,525 shares of SunCoke Energy Partners, L.P. stock. The stock was acquired at an average price of $17.54 per share, for a total transaction of $289,848.50.
On Monday, October 9th, Sun Coal & Coke Llc acquired 30,156 shares of SunCoke Energy Partners, L.P. stock. The stock was acquired at an average price of $17.31 per share, for a total transaction of $522,000.36.
On Wednesday, October 4th, Sun Coal & Coke Llc acquired 10,076 shares of SunCoke Energy Partners, L.P. stock. The stock was acquired at an average price of $17.16 per share, for a total transaction of $172,904.16.
On Tuesday, October 3rd, Sun Coal & Coke Llc acquired 9,365 shares of SunCoke Energy Partners, L.P. stock. The stock was acquired at an average price of $17.25 per share, for a total transaction of $161,546.25.
On Monday, October 2nd, Sun Coal & Coke Llc acquired 27,259 shares of SunCoke Energy Partners, L.P. stock. The stock was acquired at an average price of $17.20 per share, for a total transaction of $468,854.80.
Total BS but thanks. Next
MORE GOOD NEWS: • Abuse-deterrent formulas. FDA is preparing for an expected onslaught of generic versions of these drugs — which currently don't exist — and will release guidance for drugmakers soon. Abuse-deterrent drugs can actually lead to riskier behavior, as FDA learned with the drug Opana ER. FDA asked the maker of the purportedly safer opioid to withdraw it in June because a reformulated version led users to inject it. That led one Indiana county to have the highest number of HIV cases in the U.S.
Elite has filed the first generic ADT opioid.
https://www.usatoday.com/story/news/politics/2017/10/23/fda-chief-supports-opioid-prescription-limits-regrets-agencys-prior-inaction/774007001/
I agree my record shows a 10 bagger call = SPOT ON!!!
WHEW........boy a whole decimal place mistake. LMAO!!! OHHH NOOOOOO!!!!
LMAO; misrepresent - Sure K ...............I'd say post proof......but proof won't be forthcoming........you can't prove what doesn't exist.
Total BS - Elite has never missed and earnings call period. I have a feeling I'll be proven right yet again.
Yes I've been proving the BS to be just that for over five years and counting.
Gee more BS........Nasrat spoke about SequestOx at length during the last CC.
However, IMO, dead in the water till the warning letter gets removed.
The warning letter being removed for a start.......followed by 4 Anda in with the FDA being reviewed.
Gee try more like a fourth time.
Gee more BS and the facts prove me right.
I couldn't care less.
LMMFAO!!!! - GEE so a 10 plus bagger hit as I said it would. Got it.
Total BS.........when the volume comes it will be because the warning letter is removed and the PPS will move up yet again.